Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

APOLLO LABORATORY SCIENCE AND TECHNOLOGY SERVICES

NPI: 1992253249 · LEXINGTON, KY 40504 · Clinical Medical Laboratory · NPI assigned 09/15/2016

$2.82M
Total Medicaid Paid
82,562
Total Claims
52,324
Beneficiaries
30
Codes Billed
2018-07
First Month
2023-04
Last Month

Provider Details

Authorized OfficialSHEETS, KIM (CREDENTIALING ADMINISTRATIVE)
NPI Enumeration Date09/15/2016

Related Entities

Other providers sharing the same authorized official: SHEETS, KIM

ProviderCityStateTotal Paid
COMPLIANCE ADVANTAGE LLC NICHOLASVILLE KY $156K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 8,205 $268K
2019 28,819 $1.16M
2020 12,279 $382K
2021 18,678 $586K
2022 13,573 $389K
2023 1,008 $43K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 28,985 17,379 $1.36M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 30,818 18,591 $943K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 5,776 3,896 $163K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 1,040 818 $85K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 1,780 976 $82K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 256 247 $62K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 4,789 3,262 $50K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 5,770 3,890 $46K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 255 247 $9K
82652 268 263 $5K
87581 255 247 $4K
87486 255 247 $4K
84443 Thyroid stimulating hormone (TSH) 335 328 $2K
80053 Comprehensive metabolic panel 371 362 $2K
82607 237 231 $2K
80061 Lipid panel 299 290 $2K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 365 359 $1K
82746 135 131 $937.69
83036 Hemoglobin; glycosylated (A1C) 194 190 $789.46
84439 127 126 $494.81
83735 59 58 $165.97
84480 16 16 $153.16
84436 46 46 $131.34
82728 23 21 $100.32
86703 12 12 $94.28
86803 12 12 $91.20
83540 33 31 $89.58
87086 Culture, bacterial; quantitative colony count, urine 17 16 $71.06
82570 17 16 $0.00
84311 17 16 $0.00